Tags

Type your tag names separated by a space and hit enter

Carvedilol: the new role of beta blockers in congestive heart failure.
Am Fam Physician. 1998 Nov 01; 58(7):1627-34, 1641-2.AF

Abstract

The prognosis remains poor for patients with congestive heart failure (CHF), despite reduced mortality rates resulting from the addition of angiotensin converting enzyme inhibitors to traditional treatment regimens. Because much of the myocardial damage that occurs in patients with CHF may be related to sympathetic activation, interest in the use of beta blockers has grown. Recent studies have shown the benefits of beta blocker therapy in many patients with heart failure. Carvedilol, the first beta blocker labeled in the United States specifically for the treatment of heart failure, has been shown to improve left ventricular ejection fraction and may reduce mortality.

Authors+Show Affiliations

Grant Medical Center, Columbus, Ohio, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

9824960

Citation

Vanderhoff, B T., et al. "Carvedilol: the New Role of Beta Blockers in Congestive Heart Failure." American Family Physician, vol. 58, no. 7, 1998, pp. 1627-34, 1641-2.
Vanderhoff BT, Ruppel HM, Amsterdam PB. Carvedilol: the new role of beta blockers in congestive heart failure. Am Fam Physician. 1998;58(7):1627-34, 1641-2.
Vanderhoff, B. T., Ruppel, H. M., & Amsterdam, P. B. (1998). Carvedilol: the new role of beta blockers in congestive heart failure. American Family Physician, 58(7), 1627-34, 1641-2.
Vanderhoff BT, Ruppel HM, Amsterdam PB. Carvedilol: the New Role of Beta Blockers in Congestive Heart Failure. Am Fam Physician. 1998 Nov 1;58(7):1627-34, 1641-2. PubMed PMID: 9824960.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Carvedilol: the new role of beta blockers in congestive heart failure. AU - Vanderhoff,B T, AU - Ruppel,H M, AU - Amsterdam,P B, PY - 1998/11/24/pubmed PY - 1998/11/24/medline PY - 1998/11/24/entrez SP - 1627-34, 1641-2 JF - American family physician JO - Am Fam Physician VL - 58 IS - 7 N2 - The prognosis remains poor for patients with congestive heart failure (CHF), despite reduced mortality rates resulting from the addition of angiotensin converting enzyme inhibitors to traditional treatment regimens. Because much of the myocardial damage that occurs in patients with CHF may be related to sympathetic activation, interest in the use of beta blockers has grown. Recent studies have shown the benefits of beta blocker therapy in many patients with heart failure. Carvedilol, the first beta blocker labeled in the United States specifically for the treatment of heart failure, has been shown to improve left ventricular ejection fraction and may reduce mortality. SN - 0002-838X UR - https://www.unboundmedicine.com/medline/citation/9824960/Carvedilol:_the_new_role_of_beta_blockers_in_congestive_heart_failure_ L2 - https://www.aafp.org/link_out?pmid=9824960 DB - PRIME DP - Unbound Medicine ER -